Highlights for Q3 2020
• Annual group sales exceed 100 MNOK for the first time
• Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million)
• ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million)
• Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million)
• Upsides relating to COVID-19 pandemic is estimated at NOK 4 million for ArcticZymes and NOK 1.25 million for consumer health
• The Group delivered positive EBITDA with NOK 10.1 million (Q3 2019: NOK 0.8 million)
• Cash-flow for Q3 was positive NOK 13.6 million (Q3 2019: NOK 0.7 million) giving a cash balance of NOK 69.7 million (Q3 2019: NOK 22.1 million)
• Annual group sales exceed 100 MNOK for the first time
• Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million)
• ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million)
• Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million)
• Upsides relating to COVID-19 pandemic is estimated at NOK 4 million for ArcticZymes and NOK 1.25 million for consumer health
• The Group delivered positive EBITDA with NOK 10.1 million (Q3 2019: NOK 0.8 million)
• Cash-flow for Q3 was positive NOK 13.6 million (Q3 2019: NOK 0.7 million) giving a cash balance of NOK 69.7 million (Q3 2019: NOK 22.1 million)
